-transparent.png){kind=logo}
A bolus intravenous dose of 5-fluorouracil of 600 mg/M2 was added exactly 1 hour after methotrexate administration in an established combination program including bleomycin and cisplatin for advanced squamous cell cancer of the head and neck. Results were no better than those observed previously with the three drugs, and hematologic and mucosal toxicities were slightly worse. The overall response rate was 41% in 34 patients with recurrent or metastatic disease, with only 6% complete remissions. Median time to disease progression for responding patients was 14 weeks, compared with 10 weeks for nonresponders. Partial response had little impact on survival. Among 12 patients with far-advanced disease confined above the clavicles without prior radiotherapy, 9 (75%) achieved partial remission, but the median survival, even with later surgery or irradiation, was only 34 weeks.
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
January 1985,
The Netherlands journal of medicine,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
January 1981,
Cancer clinical trials,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
January 1987,
Head & neck surgery,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
January 1988,
NCI monographs : a publication of the National Cancer Institute,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
October 1988,
Tumori,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
October 1984,
Cancer,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
December 1989,
Journal of surgical oncology,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
January 2023,
In vivo (Athens, Greece),
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
February 1984,
Cancer,
S E Vogl, and
A Komisar, and
B H Kaplan, and
P F Engstrom, and
O H Kasule, and
L Stolbach, and
H Lerner, and
F Muggia
September 1985,
Cancer treatment reports,
